70 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51.
Max Planck Institute Of Psychiatry
Applications of Fluorine in Medicinal Chemistry.
Bristol-Myers Squibb Research And Development
Structure-Affinity Relationship Analysis of Selective FKBP51 Ligands.
Max Planck Institute Of Psychiatry
Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
Novartis Institutes For Biomedical Research
Anti-inflammatory effects of extracellular cyclosporins are exclusively mediated by CD147.
Max Planck Research Unit For Enzymology Of Protein Folding
Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control.
Max Institute Of Psychiatry
Structure-based design of novel, urea-containing FKBP12 inhibitors.
Agouron Pharmaceuticals
High-affinity FKBP-12 ligands derived from (R)-()-carvone. Synthesis and evaluation of FK506 pyranose ring replacements
TBA
Synopsis of some recent tactical application of bioisosteres in drug design.
Bristol-Myers Squibb Pharmaceutical Research And Development
Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52.
Max Planck Institute Of Psychiatry
Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52.
Max Planck Institute Of Psychiatry
Pipecolic acid derivatives as small-molecule inhibitors of the Legionella MIP protein.
University Of Wu£Rzburg
Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
Scynexis
Simultaneous identification of multiple receptors of natural product using an optimized cDNA phage display cloning.
Chinese Academy Of Sciences
Joys of molecules. 2. Endeavors in chemical biology and medicinal chemistry.
The Scripps Research Institute
Cleavage of the cyclohexyl-subunit of rapamycin results in loss of immunosuppressive activity.
Novartis Pharma
Design, synthesis and X-ray crystallographic studies of [7.3.1] and [8.3.1] macrocyclic FKBP-12 ligands
TBA
Preparation and in vitro activities of naphthyl and indolyl ether derivatives of the FK-506 related immunosuppressive macrolide ascomycin
TBA
Alkyl ether derivatives of the FK-506 related, immunosuppressive macrolide L-683,742 (C31-O-desmethyl ascomycin)
TBA
The contribution to binding of the pyranoside substituents in the excised binding domain of FK-506
TBA
Nuclear magnetic resonance fragment-based identification of novel FKBP12 inhibitors.
University Of California San Diego
Contemporary mTOR inhibitor scaffolds to diseases breakdown: A patent review (2015-2021).
University Of Hradec Kralove
Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors.
Technical University Darmstadt
Regulation of gene expression by synthetic dimerizers with novel specificity.
Ariad Gene Therapeutics
Targeting Protein Folding: A Novel Approach for the Treatment of Pathogenic Bacteria.
University Of W£Rzburg
Discovery of a novel family of FKBP12 "reshapers" and their use as calcium modulators in skeletal muscle under nitro-oxidative stress.
Universidad Del Pa£S Vasco Upv/Ehu
From Pyrazolones to Azaindoles: Evolution of Active-Site SHP2 Inhibitors Based on Scaffold Hopping and Bioisosteric Replacement.
Leibniz-Forschungsinstitut F�R Molekulare Pharmakologie (Fmp)
Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects.
Guilford Pharmaceuticals
Solid-phase synthesis of FKBP12 inhibitors: N-sulfonyl and N-carbamoylprolyl/pipecolyl amides.
Guilford Pharmaceuticals
Use of parallel-synthesis combinatorial libraries for rapid identification of potent FKBP12 inhibitors.
Guilford Pharmaceuticals
Hybrid Screening Approach for Very Small Fragments: X-ray and Computational Screening on FKBP51.
Boehringer Ingelheim Pharma
Antifungal rapamycin analogues with reduced immunosuppressive activity.
Abbott Laboratories
Fluoresceinated FKBP12 ligands for a high-throughput fluorescence polarization assay.
Bristol-Myers Squibb Pharmaceutical Research Institute
Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket.
Ariad Gene Therapeutics
Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.
Abbott Laboratories
Synthesis and cytotoxic evaluation of cycloheximide derivatives as potential inhibitors of FKBP12 with neuroregenerative properties.
Max-Planck Research Unit
Potent immunosuppressive C32-O-arylethyl ether derivatives of ascomycin with reduced toxicity.
Merck Research Laboratories
C32-O-phenalkyl ether derivatives of the immunosuppressant ascomycin: a tether length study.
Merck Research Laboratories
A Novel Decalin-Based Bicyclic Scaffold for FKBP51-Selective Ligands.
Max Planck Institute Of Psychiatry
Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design.
Bristol-Myers Squibb
C32-O-imidazol-2-yl-methyl ether derivatives of the immunosuppressant ascomycin with improved therapeutic potential.
Merck Research Laboratories
Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology.
Eberhard Karls University T£Bingen
Investigations of neurotrophic inhibitors of FK506 binding protein via Monte Carlo simulations.
Yale University
32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.
Abbott Laboratories
Structure-Based Discovery of Novel Cyclophilin A Inhibitors for the Treatment of Hepatitis C Virus Infections.
Chonnam National University
Cyclosporin analogs modified in the 3,7,8-positions: substituent effects on peptidylprolyl isomerase inhibition and immunosuppressive activity are nonadditive.
University Of Wisconsin-Madison
Chemogenomic Profiling of Human and Microbial FK506-Binding Proteins.
Max Planck Institute Of Psychiatry
Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface.
Smithkline Beecham Pharmaceuticals
Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligands.
Pfizer